Ixabepilone
Brand names: Ixempra · Active ingredient: Ixabepilone
In short: IXEMPRA is indicated in combination with capecitabine for the treatment of patients with metastatic or locally advanced breast cancer resistant to treatment with an anthracycline and a taxane, or whose cancer is taxane resistant and for whom further anthracycline therapy is contraindicated. Anthracy
What is Ixabepilone used for?
IXEMPRA is indicated in combination with capecitabine for the treatment of patients with metastatic or locally advanced breast cancer resistant to treatment with an anthracycline and a taxane, or whose cancer is taxane resistant and for whom further anthracycline therapy is contraindicated. Anthracycline resistance is defined as progression while on therapy or within 6 months in the adjuvant setting or 3 months in the metastatic setting. Taxane resistance is defined as progression while on therapy or within 12 months in the adjuvant setting or 4 months in the metastatic setting .
IXEMPRA is indicated as a single agent for the treatment of patients with metastatic or locally advanced breast cancer whose tumors are resistant or refractory to anthracyclines, taxanes, and capecitabine .
âš Boxed warning (FDA's strongest warning)
IXEMPRA in combination with capecitabine is contraindicated in patients with AST or ALT >2.5 x ULN or bilirubin >1 x ULN due to increased risk of toxicity and neutropenia-related death
.
Ixabepilone dosage
All patients must be premedicated approximately 1 hour before the infusion of IXEMPRA with:
An H
1 antagonist (eg, diphenhydramine 50 mg orally or equivalent) and
An H
2 antagonist (eg, ranitidine 150 - 300 mg orally or equivalent).
Patients who experienced a hypersensitivity reaction to IXEMPRA require premedication with corticosteroids (eg, dexamethasone 20 mg intravenously, 30 minutes before infusion or orally, 60 minutes before infusion) in addition to pretreatment with H
1 and H
2 antagonists
.
The recommended dosage of IXEMPRA is 40 mg/m
2 administered intravenously over 3 hours every 3 weeks. Calculate doses for patients with body surface area (BSA) greater than 2.2 m
2 should be calculated based on 2.2 m
2.
Evaluate patients during treatment by periodic clinical observation and laboratory tests including complete blood cell counts .
Dosage modifications for IXEMPRA for adverse reactions are shown in Table 1.
If adverse reactions recur, reduce dose by an additional 20%.
Re-treatment Criteria:
Determine dosage modifications at the start of each cycle based on nonhematologic toxicity or blood counts from the preceding cycle following the guidelines in
Table 1. Do not begin a new cycle of treatment unless the neutrophil count is at least 1500 cells/mm
3, the platelet count is at least 100,000 cells/mm
3 . Withhold IXEMPRA until nonhematologic toxicities have improved to grade 1 (mild) or resolved prior to beginning a new cycle of treatment.
Evaluate patients during treatment by periodic clinical observation and laboratory tests including complete blood cell counts
. Dosage modifications for IXEMPRA for adverse reactions are shown in
Table 1. If adverse reactions recur, reduce dose by an additional 20%.
aToxicities graded in accordance with National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events(CTCAE v3.0). …
How to take Ixabepilone — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling
Advice patients to report any numbness and tingling of the hands or feet to their healthcare provider
.
Instruct patients to immediately contact their healthcare provider if a fever of 100.5° F or greater or other evidence of potential infection such as chills, cough, or burning or pain on urination occur
.
Advise patients to immediately contact their healthcare provider if they experience urticaria, pruritus, rash, flushing, swelling, dyspnea, chest tightness, or other hypersensitivity-related symptoms following an infusion of IXEMPRA
.
Advise patients to immediately contact call their healthcare provider if they experience chest pain, difficulty breathing, palpitations, or unusual weight gain
.
Advise females of reproductive potential and pregnant women of the potential risk to a fetus. Advise patients to inform their healthcare provider of a known or suspected pregnancy.
Advise females of reproductive potential to use effective contraception during treatment with IXEMPRA and for 7 months after the last dose. …
Warnings & precautions
Do not take this medicine if: IXEMPRA is contraindicated in patients who have:
a neutrophil count <1500 cells/mm
3 or a platelet count <100,000 cells/mm
3 .
a history of severe hypersensitivity to agents containing Cremophor
® EL or its derivatives (e.g., polyoxyethylated castor oil)
.
IXEMPRA in combination with capecitabine is contraindicated in patients with AST or ALT >2.5 x ULN or bilirubin >1 x ULN
.
Severe, life-threatening, or fatal myelosuppression can occur in patients treated with IXEMPRA. Myelosuppression is dose-dependent and primarily manifests as neutropenia. In clinical studies, grade 4 neutropenia (<500 cells/mm
3) occurred in 36% of patients treated with IXEMPRA in combination with capecitabine and 23% of patients treated with single agent IXEMPRA monotherapy. Febrile neutropenia and infection with neutropenia were reported in 5% and 6% of patients treated with IXEMPRA in combination with capecitabine, respectively, and 3% and 5% of patients treated with IXEMPRA as a single agent, respectively. Neutropenia-related death occurred in 1.9% of 414 patients with normal hepatic function or mild hepatic impairment treated with IXEMPRA in combination with capecitabine. The rate of neutropenia-related deaths was higher (29%, 5 out of 17) in patients with AST or ALT >2.5 x ULN or bilirubin >1.5 x ULN
. Neutropenia-related death occurred in 0.4% of 240 patients treated with IXEMPRA as a single agent. No neutropenia-related deaths were reported in 24 patients with AST or ALT >2.5 x ULN or bilirubin >1.5 x ULN treated with IXEMPRA as a single agent.
IXEMPRA is contraindicated for use in patients with a neutrophil count of <1500 cells/mm
3.
.
Monitor patients receiving IXEMPRA for myelosuppression with frequent peripheral blood cell counts. Withhold, reduce, or discontinue IXEMPRA depending on the severity and persistence of myelosuppression
. …
Ixabepilone side effects
The following adverse reactions are discussed in greater detail in other sections.
Peripheral neuropathy
Myelosuppression
Hypersensitivity reactions
Cardiac Adverse reactions
Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in other clinical trials and may not reflect the rates observed in clinical practice.
Unless otherwise specified, assessment of adverse reactions is based on one randomized study (Study 046) and one single-arm study (Study 081). In Study 046, 369 patients with metastatic breast cancer were treated with IXEMPRA 40 mg/m
2 administered intravenously over 3 hours every 21 days, combined with capecitabine 1000 mg/m
2 twice daily for 2 weeks followed by a 1-week rest period. Patients treated with capecitabine as a single agent (n=368) in this study received 1250 mg/m twice daily for 2 weeks every 21 days. In Study 081, 126 patients with metastatic or locally advanced breast cancer were treated with IXEMPRA 40 mg/m
2 administered intravenously over 3 hours every 3 weeks.
The most common adverse reactions (≥20%) reported by patients receiving IXEMPRA were peripheral sensory neuropathy, fatigue/asthenia, myalgia/arthralgia, alopecia, nausea, vomiting, stomatitis/mucositis, diarrhea, and musculoÂskeletal pain. …
Drug interactions
Strong CYP3A4 Inhibitors
The coadministration of IXEMPRA with a strong CYP3A4 inhibitor increased ixabepilone plasma concentration, which may increase the incidence and severity of adverse reactions of IXEMPRA. Avoid coadministration of IXEMPRA with strong CYP3A4 inhibitors. If the coadministration of IXEMPRA with strong CYP3A4 cannot be avoided, reduce the dose of IXEMPRA .
Moderate or Weak CYP3A4 Inhibitors
The coadministration of IXEMPRA with moderate or weak CYP3A4 inhibitors may increase the incidence and severity of adverse reactions of IXEMPRA. Monitor for adverse reactions and reduce the dose of IXEMPRA as recommended .
Strong CYP3A4 Inducers
The coadministration of IXEMPRA with a strong CYP3A4 inducer, decreased plasma concentrations of ixabepilone, which may decrease the efficacy of IXEMPRA . Avoid the coadministration IXEMPRA with strong CYP3A4 inducers. If the coadministration of IXEMPRA with a strong CYP3A4 inducer cannot be avoided, increase the dose of IXEMPRA .
Concomitant Use of IXEMPRA and Capecitabine
No clinically meaningful differences in the pharmacokinetics of ixabepilone and capecitabine were observed when IXEMPRA was administered in combination with capecitabine (1000 mg/m
2) . …
About this medicine
IXEMPRA (ixabepilone) is a microtubule inhibitor belonging to a class of antineoplastic agents, the epothilones and their analogs. The epothilones are isolated from the myxobacterium
Sorangium cellulosum. Ixabepilone is a semisynthetic analog of epothilone B, a 16-membered polyketide macrolide, with a chemically modified lactam substitution for the naturally existing lactone.
The chemical name for ixabepilone is (1
S,3
S,7
S,10
R,11
S,12
S,16
R)-7,11 -dihydroxy-8,8,10,12,16-pentamethyl-3- [(1
E)-1 -methyl-2-(2-methyl-4-thiazolyl)ethenyl]-17-oxa-4-azabicyclo[14.1.0] heptadecane-5,9-dione, and it has a molecular weight of 506.7. Ixabepilone has the following structural formula:
IXEMPRA (ixabepilone) for injection is intended for intravenous infusion only after constitution with the supplied DILUENT and after further dilution with a specified infusion fluid
.
IXEMPRA (ixabepilone) for injection is supplied as a sterile, non-pyrogenic, single-dose vial providing 15 mg or 45 mg ixabepilone as a lyophilized white powder. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 241f0b1e-8b95-470d-876f-bf1804daaf18. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate